Vaccination trial to synovial sarcoma patients using HLA-A24 restricted SYT-SSX junction peptide, adjuvant, and HLA-A24 anchor substituted peptide

Vaccination trial to synovial sarcoma patients using HLA-A24 restricted SYT-SSX junction peptide, adjuvant, and HLA-A24 anchor substituted peptide - Peptide vaccination to synovial sarcoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001359

Enrollment

Registered

2008-10-01

Start date

2004-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

synovial sarcoma

Interventions

Total 6 times, every two weeks vaccination including 1mg of peptide and adjuvant.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: histologically and genetically (SYT-SSX 1 or SYT-SSX 2 positive) confirmed, unresectable synovial sarcoma, HLA-A2402 positive, between 20 and 70 years old, ECOG performance status between 0 and 3, informed consent

Exclusion criteria

Exclusion criteria: prior chemotherapy, steroid therapy, or other immunotherapy within the past 4 weeks, presence of other cancers, immunodefficiency, history of splenectomy, severe cardiac insufficiency, acute infection, hematopoietic failure , anti-coagulant therapy

Design outcomes

Primary

Measure	Time frame
Toxicity and adverse effect between first vaccination and 2 weeks after 6th vaccination.	—

Secondary

Measure	Time frame
delayed type hypersesitivity, frequency of T lymphocyte responsive to HLA-A24 restricted peptide, cytotoxic T-lymphocyte acitivity, anti-tumor effect	—

Countries

Japan

Contacts

Public ContactTakuro Wada

Sapporo Medical University Orthopaedic Surgery

011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026